{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=30",
    "query": {
      "condition": "Breast Adenocarcinoma",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 700,
    "total_pages": 70,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:57:12.114Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00433511",
      "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4994,
      "start_date": "2007-11-02",
      "completion_date": "2027-02-20",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 840,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433511"
    },
    {
      "nct_id": "NCT00680667",
      "title": "Clinical Trial of Trametes Versicolor in Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Coriolus versicolor extract",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 75 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2007-04",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Kenmore, Washington",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Kenmore",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680667"
    },
    {
      "nct_id": "NCT01351103",
      "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "BRAF Mutant Colorectal Cancer",
        "Melanoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Cervical Squamous Cell Cancer",
        "Esophageal Squamous Cell Cancer",
        "Lung Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "LGK974",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2011-12-01",
      "completion_date": "2024-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351103"
    },
    {
      "nct_id": "NCT00749437",
      "title": "Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "3-dimensional conformal accelerated partial breast irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2008-10",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2012-06-14",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749437"
    },
    {
      "nct_id": "NCT03576131",
      "title": "GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Pancreatic Cancer",
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1029 (HexaBody®-DR5/DR5)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2018-04-30",
      "completion_date": "2021-10-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576131"
    },
    {
      "nct_id": "NCT00002920",
      "title": "S9630, Medroxyprogesterone in Treating Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "medroxyprogesterone",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 313,
      "start_date": "1997-03",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-31",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 122,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002920"
    },
    {
      "nct_id": "NCT00909909",
      "title": "Radiation Therapy in Treating Women With Early Stage Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "External beam boost",
          "type": "RADIATION"
        },
        {
          "name": "whole breast irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2009-05-13",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 4,
      "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey • Somerset, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Somerset",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00909909"
    },
    {
      "nct_id": "NCT02898207",
      "title": "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic High Grade Fallopian Tube Serous Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Primary Peritoneal Serous Adenocarcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent High Grade Ovarian Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Triple-Negative Breast Carcinoma",
        "Refractory Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Serous Adenocarcinoma",
        "Refractory Triple-Negative Breast Carcinoma",
        "Unresectable High Grade Fallopian Tube Serous Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Primary Peritoneal Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onalespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-05-19",
      "completion_date": "2022-01-14",
      "has_results": true,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02898207"
    },
    {
      "nct_id": "NCT06943521",
      "title": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Biliary Tract Cancer",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Breast Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Prostate Cancer",
        "Urothelial Carcinoma",
        "Neuroendocrine Tumor (NET)",
        "Neuroendocrine Carcinoma (NEC)",
        "Soft Tissue Sarcoma",
        "Nuclear Protein in Testis (NUT) Carcinoma"
      ],
      "interventions": [
        {
          "name": "MT-4561",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tanabe Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-04-18",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06943521"
    },
    {
      "nct_id": "NCT03157128",
      "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "Colon Cancer",
        "Any Solid Tumor"
      ],
      "interventions": [
        {
          "name": "LOXO-292",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 857,
      "start_date": "2017-05-02",
      "completion_date": "2027-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-15T00:57:12.114Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03157128"
    }
  ]
}